Psychoneuroendocrinology 103, 284295
#MentalHealthCareers #LMFT #Counseling To view or add a comment, sign in If there's one thing I've learned as a divorce attorney (and having learned only one thing may well be the case), it's this: Maximizing for a potential marriage partner's physical attractiveness (if you're a guy), or maximizing for access to resources (if you're a gal), is no where near as important as maximizing for mental health
But more important than modifying risk factors, the GLP-1 RAs provide patients with type 2 diabetes on average a 14% relative risk reduction for major cardiovascular events, including: Cardiovascular death Heart attack Stroke Three GLP-1 RAs have been indicated by the FDA to reduce heart disease risk in people with type 2 diabetes who have or are at high risk for blockages of arteries of the heart, brain, and legs, also known as atherosclerotic cardiovascular disease (ASCVD): Dulaglutide, which is branded as Trulicity and is currently the only GLP-1 RA approved for cardiovascular disease risk reduction in patients with or without established ASCVD Liraglutide, which is branded as Victoza and was the first GLP-1 RA to show efficacy for heart benefits in a clinical trial Semaglutide, which has been increasingly prescribed off-label as a weight-loss medication under the brand name Ozempic Whereas we are still exploring the biological mechanisms of how GLP-1 Ras benefit the heart, the body of evidence we have at present is already revolutionizing the care of patients with type 2 diabetes
TB-500 operates primarily through actin polymerization and cell migration signaling, without the angiogenic mechanism that defines research into this compound
